Anti-Axl Antagonistic Antibodies
AssigneesBergen TeknologioverføRing AS, Bergenbio Asa
InventorsDavid Robert MICKLEM, Sergej KIPRIJANOV, James Bradley LORENS, Lavina AHMED, Linn NILSSON, Tone SANDAL
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to antibodies that specifically bind a novel epitope on the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
Claims19
-33. (canceled)
A method of treating a fibrotic disorder in a subject, comprising administering to the subject an effective amount of:
- (i) an antibody that binds Axl and which comprises:
- an antibody heavy chain variable region (VH) domain comprising a VH CDR1, a VH CDR2, and a VH CDR3 of SEQ ID NO:
- 2;
- and, an antibody light chain variable region (VL) domain selected from the group consisting of SEQ ID NO:
- 3 and SEQ ID NO:
- 4;
- or an immunoconjugate thereof;
- or
- (ii) an antibody that binds Axl and which comprises:
- an antibody VH domain selected from the group consisting of SEQ ID NO:
- 2 and SEQ ID NO:
- 1;
- and, an antibody VL domain comprising a VL CDR1, a VL CDR2, and a VL CDR3 of SEQ ID NO:
- 3;
- or an immunoconjugate thereof.
A kit comprising an antibody that binds Axl or an immunoconjugate thereof, wherein the antibody comprises:
- (i) an antibody heavy chain variable region (VH) domain comprising a VH CDR1, a VH CDR2, and a VH CDR3 of SEQ ID NO:
- 2;
- and, an antibody light chain variable region (VL) domain selected from the group consisting of SEQ ID NO:
- 3 and SEQ ID NO:
- 4;
- or
- (ii) an antibody VH domain selected from the group consisting of SEQ ID NO:
- 2 and SEQ ID NO:
- 1;
- and, an antibody VL domain comprising a VL CDR1, a VL CDR2, and a VL CDR3 of SEQ ID NO:
- 3.
A method for reducing EGFR phosphorylation in a cancer cell, wherein the cancer cell is resistant to an EGFR antagonist, and wherein the cancer cell comprises an Axl activating mutation or an Axl gene amplification, comprising the step of contacting the cancer cell with an anti-Axl antibody and an EGFR antagonist.
Dependencies are inferred from the claim text.